Background and Purpose—Obesity has been associated with increased cardiovascular risk
in atrial fibrillation, but little is known in elderly patients with atrial fibrillation. Methods—Post …

Background—Patients with atrial fibrillation (AF) often take multiple medications. Methods
and Results—We examined characteristics and compared adjusted outcomes between …

Background—Nonvalvular atrial fibrillation is common in elderly patients, who face an
elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor …

Background A global, randomized clinical trial indicated the efficacy and safety of apixaban
in stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). However, data in …

Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …

Objectives To investigate effects of appropriately and inappropriately dosed
apixaban/rivaroxaban versus warfarin on effectiveness and safety outcomes in patients with …

Background Apixaban is a non–vitamin K oral anticoagulant approved for prevention of
stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Current …

Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …

Abstract Background/Objectives Adverse bleeding events happened more frequently among
individuals with, or at risk of, a low body mass index (BMI) than others. Despite increasing …

Abstract Study Objective Direct oral anticoagulants are the standard of care for venous
thromboembolism (VTE) treatment. These agents are recommended regardless of patient …